Dr. Charlotte Ling is a Professor at Lund University and a principal investigator of the Epigenetics and Diabetes Unit at Lund University Diabetes Centre (LUDC), Sweden. She obtained her PhD in Endocrinology at University of Gothenburg, Sweden in 2002. After a postdoc at Lund University, where she studied genetics of type 2 diabetes, she dedicated her research to the study of epigenetic mechanisms causing type 2 diabetes and metabolic disease. Her research group has over the last two decades pioneered the field of epigenetics in type 2 diabetes. They have made numerous groundbreaking discoveries such as identification of genome-wide epigenetic modifications in pancreatic islets, skeletal muscle, adipose tissue and the liver from patients with type 2 diabetes compared with non-diabetic controls. Dr. Ling’s group has also shown that genetic and non-genetic factors such as SNPs, exercise, diet, obesity and age alter the genome-wide epigenetic pattern in key human tissues affecting type 2 diabetes. More recently, her group has developed blood-based epigenetic biomarkers that may be used for precision medicine. Dr. Ling is frequently invited to write review papers and book chapters and give lectures (e.g. ADA, IDF, Keystone and Endocrine Society) on the topic ‘Epigenetics and Type 2 Diabetes’. Dr. Ling has been received numerous research grants and awards, for example the Distinguished professor award from The Swedish Research Council, European Commission grants (ERC, MC and H2020), Novo Nordisk Distinguished Investigator Grant and EFSD/NNF Precision Diabetes Medicine runner up award. She has published 135 original publications, 20 invited review papers and 10 book chapters since 1999 including papers in Cell Metabolism, Nature Communications, Science Translational Medicine, JCI, PNAS and Diabetes Care. Her H-index is 73 and she has ~23,700 citations.